It was obvious from the very beginning that GLP-1 agonist drugs are not a panacea but a well-disguised time bomb that would be a blockbuster for sale, but a disaster for long-term health. Namely, the weight loss those drugs induce is largely driven by them curbing appetite, which effectively forces a person to fast. Prolonged fasting alone has a variety of negative effects, now reluctantly being recognized by mainstream medicine. However, GLP-1 agonism has known pancreatotoxic effects and has been linked to the deadly pancreatic cancer as well as neurodegenerative conditions long before those drugs hit the market. If something is neurotoxic, it is expected to have a negative effect on all portions of the nervous system, including the retina (which is part of the central nervous system). In corroboration, the study below suggests that GLP-1 agonist drugs may increase risk for a condition known as diabetic retinopathy (DR). That condition is a morbidity secondary to diabetes, and GLP-1 agonist drugs are supposed to prevent and ameliorate the latter. Given the increased risk of DR as a result of GLP-1 agonists, one may conjecture that those drugs do not really have a beneficial effects on the course of diabetes, but somehow simply mask its symptoms while the pathology continues to accelerate. When we add the now known increased risks of gastroparesis, and general vision loss not-related to diabetic retinopathy, it quickly becomes clear that it is best to stay away from these drugs until the safety profile is better known.
“…A recent study has identified a potential link between GLP-1 receptor agonist drugs, commonly prescribed for diabetes and weight management, and an increased risk of serious eye diseases. Researchers found that patients using these medications may face a heightened likelihood of developing conditions such as diabetic retinopathy, which can lead to vision loss if untreated. The findings raise concerns about the long-term safety profile of these widely used drugs. The study analyzed data from multiple patient groups over an extended period to assess the impact of GLP-1 drugs on ocular health. Diabetic retinopathy emerged as a key concern, with researchers noting that the progression of this condition appeared more pronounced in individuals taking GLP-1 receptor agonists compared to those on alternative treatments. While the exact mechanism behind this association remains unclear, experts suggest further investigation is necessary to determine whether the drugs directly contribute to retinal damage or exacerbate pre-existing conditions. The findings underscore the importance of monitoring eye health in patients prescribed these medications and may prompt additional scrutiny from regulatory agencies moving forward.”
